Transgenic mice that were given the antibody aducanumab only five days prior to initial manifestation of amyloid beta deposition associated with Alzheimer's disease only had significantly reduced amyloid beta accumulation and pathology after six months, compared with those that were given other antibodies. The findings in Nature Neuroscience indicate the early aducanumab administration enabled removal of amyloid beta seed aggregation, but more studies are needed to determine more antibodies that identify various aggregation seeds, said researcher Mathias Jucker.
Early aducanumab treatment may curb Alzheimer's
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.